Jonathan Miller
Stock Analyst at Evercore ISI
(1.68)
# 3,494
Out of 4,634 analysts
55
Total ratings
48%
Success rate
0.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Rated: Buy | $19 → $14 | $8.99 | +55.73% | 4 | Aug 10, 2026 | |
| NTLA Intellia Therapeutics | Upgraded: Buy | $16 → $24 | $12.02 | +99.67% | 6 | Aug 7, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintained: Buy | $23 | $11.14 | +106.46% | 5 | Jul 20, 2026 | |
| EDIT Editas Medicine | Maintained: Buy | $15 | $2.81 | +433.81% | 3 | May 27, 2026 | |
| NKTX Nkarta | Maintained: Buy | $9 | $2.46 | +265.85% | 1 | May 18, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Buy | $74 → $76 | $53.51 | +42.03% | 2 | May 11, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $23 → $22 | $16.41 | +34.06% | 5 | May 11, 2026 | |
| TRDA Entrada Therapeutics | Maintained: Buy | $25 | $6.95 | +259.71% | 2 | May 5, 2026 | |
| ERAS Erasca | Maintained: Buy | $11 → $24 | $18.12 | +32.45% | 2 | Apr 28, 2026 | |
| PMVP PMV Pharmaceuticals | Maintained: Buy | $18 → $4 | $1.23 | +225.20% | 2 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $15 | $7.70 | +94.81% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $48 | $24.16 | +98.68% | 3 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 → $13 | $1.66 | +683.13% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $28.72 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.06 | - | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $5.02 | +19.52% | 1 | Nov 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $13.81 | -13.11% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $7.14 | n/a | 2 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.08 | n/a | 3 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.69 | n/a | 1 | Sep 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.61 | n/a | 2 | May 5, 2021 |
Arvinas
Aug 10, 2026
Rated: Buy
Price Target: $19 → $14
Current: $8.99
Upside: +55.73%
Intellia Therapeutics
Aug 7, 2026
Upgraded: Buy
Price Target: $16 → $24
Current: $12.02
Upside: +99.67%
4D Molecular Therapeutics
Jul 20, 2026
Maintained: Buy
Price Target: $23
Current: $11.14
Upside: +106.46%
Editas Medicine
May 27, 2026
Maintained: Buy
Price Target: $15
Current: $2.81
Upside: +433.81%
Nkarta
May 18, 2026
Maintained: Buy
Price Target: $9
Current: $2.46
Upside: +265.85%
CRISPR Therapeutics AG
May 11, 2026
Maintained: Buy
Price Target: $74 → $76
Current: $53.51
Upside: +42.03%
Janux Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $23 → $22
Current: $16.41
Upside: +34.06%
Entrada Therapeutics
May 5, 2026
Maintained: Buy
Price Target: $25
Current: $6.95
Upside: +259.71%
Erasca
Apr 28, 2026
Maintained: Buy
Price Target: $11 → $24
Current: $18.12
Upside: +32.45%
PMV Pharmaceuticals
Apr 13, 2026
Maintained: Buy
Price Target: $18 → $4
Current: $1.23
Upside: +225.20%
Apr 13, 2026
Maintained: Buy
Price Target: $13 → $15
Current: $7.70
Upside: +94.81%
Mar 9, 2026
Reiterated: Buy
Price Target: $33 → $48
Current: $24.16
Upside: +98.68%
Mar 9, 2026
Maintained: Buy
Price Target: $1 → $13
Current: $1.66
Upside: +683.13%
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $28.72
Upside: -
Jan 26, 2026
Maintained: Buy
Price Target: n/a
Current: $4.06
Upside: -
Nov 28, 2025
Maintained: Buy
Price Target: $6
Current: $5.02
Upside: +19.52%
Sep 30, 2025
Maintained: Buy
Price Target: $12
Current: $13.81
Upside: -13.11%
Oct 2, 2024
Rated: Buy
Price Target: n/a
Current: $7.14
Upside: n/a
Sep 16, 2024
Maintained: Buy
Price Target: n/a
Current: $4.08
Upside: n/a
Sep 2, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $1.69
Upside: n/a
May 5, 2021
Reiterated: Buy
Price Target: n/a
Current: $8.61
Upside: n/a